HomeAI · summaries
Storia in 3 fonti
Vaderis gets $152M to run Phase 3 of rare bleeding disorder treatment
Vaderis Therapeutics raised a Series B to run a Phase 3 study of its AKT inhibitor engasertib in a rare blood disorder called hereditary hemorrhagic telangiectasia.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Vaderis hauls in $152M to test an AKT-targeting drug
The startup is one of at least a few young companies zeroing in on the rare bleeding disorder, hereditary hemorrhagic telangiectasia, with a more precise AKT blocker.
- ·
endpoints.news
Vaderis gets $152M to run Phase 3 of rare bleeding disorder treatment
Vaderis Therapeutics raised a Series B to run a Phase 3 study of its AKT inhibitor engasertib in a rare blood disorder called hereditary hemorrhagic telangiectasia.
